Zhang Wen, Guo Nannan, Yu Changhai, Wang Hongwei, Zhang Yiming, Xia Hui, Yu Jiangqi, Lu Jiangyang
Department of Cardiothoracic Surgery, The First Affiliated Hospital of General Hospital of the Chinese People's Liberation Army, Fucheng Road 51, Beijing 100048, People's Republic of China.
Tumour Biol. 2012 Dec;33(6):2209-16. doi: 10.1007/s13277-012-0482-4. Epub 2012 Aug 14.
About 80 % of lung cancers are carcinomas that are classified histologically as non-small-cell lung carcinoma (NSCLC) and targeted chemotherapy of this cancer is currently based on sensitivity of the primary tumor to specific drugs. The purpose of this study was to compare the levels of four serum markers of cancer and the levels of six molecular markers which are possibly associated with drug selection in the primary tumors and metastatic lymph nodes of 39 consecutive NSCLC patients who were admitted to a single institution in China. Serum markers of cancer (neuron-specific enolase, carcinoembryonic antigen (CEA), cancer antigen 125, cytokeratin fragment 21-1) were measured by an automated electrochemiluminescence system and molecular markers (multidrug resistance protein 1, LDL receptor-related protein, ribonucleotide reductase M1, epidermal growth factor receptor, excision repair cross-complementing gene 1, and breast cancer 1) were measured by immunohistochemistry of the primary tumors and metastatic lymph nodes. The results indicate that the serum level of CEA was higher in NSCLC patients with adenocarcinoma relative to those with squamous cell carcinoma, but no significant differences in the other serum markers. Expression of excision repair cross-complementing gene 1 was significantly different in the primary tumors and metastatic sites of NSCLC patients with adenocarcinoma, but there were no other significant differences. This study provides an initial step toward the development of individualized chemotherapy of NSCLC based on measurement of molecular markers in the primary tumors and metastatic lymph nodes.
约80%的肺癌为组织学上分类为非小细胞肺癌（NSCLC）的癌，该癌症的靶向化疗目前基于原发性肿瘤对特定药物的敏感性。本研究的目的是比较39例连续入住中国某单一机构的NSCLC患者原发性肿瘤和转移淋巴结中四种癌症血清标志物水平以及六种可能与药物选择相关的分子标志物水平。癌症血清标志物（神经元特异性烯醇化酶、癌胚抗原（CEA）、癌抗原125、细胞角蛋白片段21-1）通过自动电化学发光系统检测，分子标志物（多药耐药蛋白1、低密度脂蛋白受体相关蛋白、核糖核苷酸还原酶M1、表皮生长因子受体、切除修复交叉互补基因1和乳腺癌1）通过原发性肿瘤和转移淋巴结的免疫组织化学检测。结果表明，腺癌NSCLC患者的CEA血清水平高于鳞状细胞癌患者，但其他血清标志物无显著差异。腺癌NSCLC患者原发性肿瘤和转移部位的切除修复交叉互补基因1表达有显著差异，但无其他显著差异。本研究为基于原发性肿瘤和转移淋巴结中分子标志物测量开展NSCLC个体化化疗迈出了第一步。
